PGI20 ECONOMIC VALUATION MODELING FOR ASSESSING BIOTECHNOLOGY/PHARMACEUTICAL DEVELOPMENTAL OPPORTUNITIES  by Shane, LG et al.
A124 Abstracts
for the trial baseline, and the model for the relative treatment
effects which the trials were designed to estimate. Methods for
selecting models on the basis of goodness of ﬁt are suggested.
CONCLUSIONS: The models are implemented in the Bayesian
Markov chain Monte Carlo WinBUGS package, so that para-
meter estimation and decision modeling can be integrated into a
single process.
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OBJECTIVES: To assess the cost per symptom occurrence of
GERD management in primary care of naïve and relapser
patients in Campania, a region of southern Italy. METHODS:
Prospective cost of GERD management has been calculated in
patients who consulted 259 general practitioners (GPs). Direct
costs to the National Health Service (tariffs 2005) including
drugs, physicians’ visits and diagnostic tests were calculated and
expressed in Euro. Mann-Withney test was used where indicated.
To investigate the association between cost and its potential
determinants (age, sex, disease severity and clinical approach—
therapeutic/ empirical or diagnostic) bootstrap analysis was
used. Data are expressed as mean ± SEM. Societal perspective
was adopted. RESULTS: We studied 1343 patients with GERD,
456 naïve (48% males; mean and age range: 49.4y, 18–89) and
887 relapser (51%; 55.2, 18–98). Overlapped dyspeptic symp-
toms were found in 75.2% and 73.1% of naïve and relapser
patients respectively. Therapeutic approach was preferred by GPs
in both groups (naïve 55.9%; relapser 72.8%). The cost of
GERD management was signiﬁcantly different between naïve
and relapser groups (€90.4 ± 4.04 vs. 122.1 ± 4.15; p < 0.0001).
This difference was partially attributable to prescribed drugs
(€47.6 ± 2.85 vs. €83.4 ± 3.47; p < 0.0001). Proton pump
inhibitors were the most prescribed drugs by GPs (naïve 62.5%;
relapser 67.5%). Age, male sex, disease severity and diagnostic
approach were signiﬁcantly (p < 0.05) associated with cost
increase in both groups. CONCLUSIONS: In primary care
second or following approach of GERD patient is more costly
respect to that of naive. Disease severity and diagnostic approach
increase the cost of GERD management independently to time
approach.
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OBJECTIVES: Reimbursement authorities are faced with 
decision-making for numerous launches of biotechnology/
pharmaceutical technologies with uncertain “value-for-money”.
Concurrently, biotechnology/pharmaceutical companies are
assessing their developmental pipeline. An economic modeling
application, based on cost-effective methodology, is illustrated
which helps the manufacturer analyze and predict cost-effective
patient populations, market access value, and pricing for future
product opportunities by considering payers’ willingness-to-
pay thresholds (WTPT). METHODS: A deterministic Markov
Excel® model was developed comparing chronic liver disease
populations treated with a new product, Drug X, to established
standard care. The US, Italy, UK, and German health care system
perspectives were evaluated; methods followed respective
country economic guidelines. Literature review provided disease
transitions, utilities, resource utilization and direct cost esti-
mates. Physicians validated disease progression rates, treat-
ment patterns and resource utilization. Quality-adjusted life
expectancy, total lifetime costs and incremental cost-utility ratios
between strategies were estimated. A uniﬁed analysis assessed the
weighted incremental cost-utility outcomes and trade-offs for
sub-population scenarios. Crystal Ball® software predicted drug
price ranges for various scenarios at ﬁxed payer’s WTPT. Prob-
abilistic stochastic Monte Carlo sensitivity analysis was con-
ducted for all input parameters. RESULTS: The model estimated
that the most cost-effective sub-populations included the F3 and
F4 Metavir patients, compared to the broadest population. At a
payer’s WTPT of $50,000/QALY, the incremental drug efﬁcacy
required in F3 and F4 to be cost-effective over 20 years was pre-
dicted at 14% and 43.5%, for annual price ranges of US$1500
and US$4000, respectively. Sensitivity analysis determined the
critical drivers: incremental drug efﬁcacy/safety rates, price,
patient sub-population and utility values. CONCLUSION: Eco-
nomic valuation modeling has been inﬂuential in providing guid-
ance on payer market access dynamics; predicting cost-effective
positioning and treatment populations; and projecting pricing
for new product opportunities. Increasingly, manufacturers’ rec-
ognize that this approach may reduce product development risk
by establishing more realistic estimates of market potential,
pricing and societal need.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a prevalent
functional gastrointestinal dysmotility disorder. This study aimed
to estimate the burden of illness of a Dutch population of 
community dwelling patients suffering from IBS. METHODS:
Patients identiﬁed at community pharmacies, using mebeverine
as a proxy for IBS, were administered a questionnaire regarding
1) the Rome II criteria for IBS, 2) predominant type of stool
during complaints, 3) severity of symptoms (abdominal pain and
discomfort), 4) generic and disease-speciﬁc quality of life, 5)
current health status (utilities), and 6) loss of productivity.
RESULTS: A total of 375 users of mebeverine were identiﬁed of
which 169 patients met the Rome II criteria for IBS, and were
included in the study. More than half (58%) of the IBS patients
reported severe abdominal pain and complaints. Generic and
disease-speciﬁc quality of life outcomes showed impairment on
all dimensions. The current health status perceived by IBS
patients was 62% (95%CI: 60–66) of full health. Transformed
to population utilities, health status was 0.67 (95%CI:
0.65–0.68). The loss in productivity of IBS patients was 1.8 days
(95%CI: 1.1–2.5) per month. CONCLUSIONS: This study con-
ﬁrmed that the burden of illness of IBS in The Netherlands is
substantial. IBS patients treated with mebeverine experienced
low quality of life and suffered from severe pain. Based on these
results, more attention for the diagnosis and treatment of IBS
seems to be justiﬁed.
